| Incyteannounced 31 Oct 2023 |
File the IND for INCB100658, a JAK2V617F-targeting small molecule inhibitor |
No record found31 Dec 2023 |
| Incyteannounced 31 Oct 2023 |
Share additional data from ruxolitinib twice-daily combination studies with zilurgisertib and INCB57643 |
Met31 Dec 2023 |
| Incyteannounced 31 Oct 2023 |
Initiate a Phase 3 study of povorcitinib in prurigo nodularis |
No record found31 Dec 2024 |
| Incyteannounced 1 Aug 2023 |
Enter the clinic with auremolimab, an anti-IL-15Rβ monoclonal antibody |
Met31 Dec 2023 |
| Incyteannounced 2 May 2023 |
Initiate the first-in-human study of INCA33989 in MF and ET |
Met31 Dec 2023 |
| Incyteannounced 7 Feb 2023 |
Report final results from the Phase 3 trial of parsaclisib as an add-on to ruxolitinib |
No record found31 Dec 2023 |
| Incyteannounced 7 Feb 2023 |
Initiate Phase 1/1b trial of INCB99280 with adagrasib |
No record found31 Dec 2023 |
| Incyteannounced 7 Feb 2023 |
Present updated data for zilurgisertib combined with ruxolitinib in myelofibrosis |
Met31 Dec 2023 |
| Incyteannounced 7 Feb 2023 |
Begin clinical trials of INCA33989 (mCALR antibody) |
No record found31 Dec 2023 |
| Incyteannounced 7 Feb 2023 |
Present updated data for oral PD-L1 programme INCB99280 and INCB99318 |
No record found31 Dec 2023 |
| Incyteannounced 7 Feb 2023 |
Report Phase 2 results for povorcitinib in vitiligo and prurigo nodularis |
Met31 Dec 2023 |
| Incyteannounced 1 Nov 2022 |
Begin clinical development of auremolimab |
No record found31 Dec 2023 |
| Incyteannounced 2 Aug 2022 |
Initiate a Phase 3 study of povorcitinib in hidradenitis suppurativa |
Met31 Dec 2022 |
| Incyteannounced 3 Aug 2021 |
Initiate a Phase 3 trial of parsaclisib in autoimmune hemolytic anemia |
No record found31 Dec 2021 |
| Incyteannounced 3 Aug 2021 |
Submit a regulatory application seeking approval of ruxolitinib cream in vitiligo |
No record found31 Dec 2021 |
| Incyteannounced 4 May 2021 |
Initiate pivotal trials for tafasitamab and LIMBER programs |
No record found31 Dec 2021 |
| Incyteannounced 4 May 2021 |
Start the topMIND proof-of-concept trial of tafasitamab plus parsaclisib |
No record found31 Dec 2021 |
| Incyteannounced 9 Feb 2021 |
Submit a new drug application for parsaclisib in relapsed or refractory lymphoma to the FDA |
Met31 Dec 2021 |
| Incyteannounced 5 Nov 2020 |
Report topline results from the Phase 3 RUXCOVID study |
Met31 Dec 2020 |
| Incyteannounced 4 Aug 2020 |
Submit a New Drug Application for ruxolitinib cream |
Met31 Dec 2020 |
| Incyteannounced 5 May 2020 |
Report results of the Phase 3 REACH 3 trial in chronic GVHD |
Met31 Dec 2020 |
| Incyteannounced 13 Feb 2020 |
Submit NDA for ruxolitinib cream in atopic dermatitis to regulators |
Met31 Dec 2020 |
| Incyteannounced 29 Oct 2019 |
Report initial results from the TRuE-AD Phase 3 program of ruxolitinib cream in atopic dermatitis |
Met30 Jun 2020 |
| Incyteannounced 29 Oct 2019 |
Report initial results from the TRuE-V Phase 3 program of ruxolitinib cream in vitiligo |
Met31 Dec 2021 |
| Incyteannounced 30 Jul 2019 |
Complete enrollment in the continuous dosing cohort of the pemigatinib bladder cancer Phase 2 trial |
No record found31 Dec 2019 |
| Incyteannounced 30 Jul 2019 |
Begin Phase 3 development of ruxolitinib cream in patients with vitiligo |
Met31 Dec 2019 |
| Incyteannounced 14 Feb 2019 |
Submit NDA seeking approval of pemigatinib for second-line FGFR2 translocated cholangiocarcinoma |
Met30 Sep 2019 |
| Incyteannounced 14 Feb 2019 |
Initiate pivotal tumor-agnostic trial of pemigatinib in FGF/FGFR driver-activated solid tumors |
No record found31 Dec 2019 |
| Incyteannounced 14 Feb 2019 |
Report Phase 3 data for ruxolitinib cream in atopic dermatitis |
Met31 Dec 2020 |
| Incyteannounced 30 Oct 2018 |
Begin Phase 2 trials of INCMGA0012 in MSI-high endometrial, Merkel cell and anal cancers |
Met31 Dec 2018 |
| Incyteannounced 30 Oct 2018 |
Begin Phase 3 GRAVITAS-309 trial of itacitinib in chronic GVHD |
Met30 Jun 2019 |
| Incyteannounced 30 Oct 2018 |
Report Phase 2 data from ruxolitinib cream trial in vitiligo |
Met31 Dec 2019 |
| Incyteannounced 30 Oct 2018 |
Submit a new drug application for pemigatinib in advanced cholangiocarcinoma |
Met31 Dec 2019 |
| Incyteannounced 1 May 2018 |
Report data from the Phase 2 trial of topical ruxolitinib in atopic dermatitis |
Met31 Dec 2018 |
| Incyteannounced 1 May 2018 |
Enter clinical trials with INCAGN2390 (TIM-3) |
No record found31 Dec 2018 |
| Incyteannounced 1 May 2018 |
Enter clinical trials with INCAGN2385 (LAG-3) |
No record found31 Dec 2018 |
| Incyteannounced 15 Feb 2018 |
Report initial progression-free survival results of the ECHO-301 trial of epacadostat in melanoma |
Met30 Jun 2018 |
| Incyteannounced 15 Feb 2018 |
Enter clinical trials with INCB81776 (AXL/MER) |
No record found31 Dec 2018 |
| Incyteannounced 15 Feb 2018 |
Report initial data from the trial of INCB54828 in cholangiocarcinoma |
Met31 Dec 2018 |
| Incyteannounced 31 Oct 2017 |
Initiate the next wave of eight pivotal Phase 3 epacadostat trials with PD-1 antagonists |
No record found31 Dec 2017 |
| Incyteannounced 31 Oct 2017 |
Deliver REACH1 pivotal trial results for ruxolitinib in steroid-refractory acute GVHD |
Met30 Jun 2018 |
| Incyteannounced 31 Oct 2017 |
Deliver ECHO-301 Phase 3 data for epacadostat plus pembrolizumab in melanoma |
Met30 Jun 2018 |
| Incyteannounced 31 Oct 2017 |
Begin Phase 3 trial of epacadostat with durvalumab in Stage III NSCLC |
No record found30 Jun 2018 |
| Incyteannounced 31 Oct 2017 |
Submit sNDA seeking accelerated approval of ruxolitinib for steroid-refractory acute GVHD |
Met31 Dec 2018 |
| Incyteannounced 27 Oct 2017 |
Close the MGA012 exclusive global collaboration and license agreement with MacroGenics |
Met31 Dec 2017 |
| Incyteannounced 4 May 2017 |
Begin Phase 3 trials of epacadostat with nivolumab in NSCLC and head & neck cancer |
No record found31 Dec 2017 |
| Incyteannounced 4 May 2017 |
Begin Phase 1/2 dose-escalation trial of INCB62079 in hepatocellular carcinoma |
No record found31 Dec 2017 |
| Incyteannounced 4 May 2017 |
Begin the Phase 3 REACH3 trial of ruxolitinib in steroid-refractory chronic GVHD |
No record found31 Dec 2017 |
| Incyteannounced 14 Feb 2017 |
Begin Phase 2 CITADEL-202 trial in diffuse large B cell lymphoma |
No record found30 Jun 2017 |
| Incyteannounced 14 Feb 2017 |
Begin pivotal ruxolitinib program for essential thrombocythemia |
No record found31 Dec 2017 |
| Incyteannounced 14 Feb 2017 |
Enter proof-of-concept clinical trials with FGFR4 inhibitor INCB62079 |
No record found31 Dec 2017 |
| Incyteannounced 14 Feb 2017 |
Initiate new pivotal trials in at least six indications from the late-stage portfolio |
No record found31 Dec 2017 |
| Incyteannounced 14 Feb 2017 |
Begin Phase 3 trials of epacadostat with pembrolizumab in four additional tumor types |
No record found31 Dec 2017 |
| Incyteannounced 14 Feb 2017 |
Begin Phase 2 trial of topical ruxolitinib in vitiligo |
Met31 Dec 2017 |
| Incyteannounced 14 Feb 2017 |
Enter global pivotal program for itacitinib in treatment-naive acute GVHD |
Met31 Dec 2017 |
| Incyteannounced 14 Feb 2017 |
Begin REACH2 and REACH3 randomized Phase 3 trials in graft-versus-host disease |
No record found31 Dec 2017 |
| Incyteannounced 21 Dec 2016 |
Close the collaboration and share purchase with Merus N.V |
Met31 Mar 2017 |
| Incyteannounced 1 Nov 2016 |
Report data from the INCB39110 Phase 1/2 graft versus host disease trial |
No record found31 Dec 2016 |
| Incyteannounced 9 Aug 2016 |
Present updated Phase 1 ECHO-202 data at the ESMO congress |
Met31 Oct 2016 |
| Incyteannounced 9 Aug 2016 |
Start the Phase 2 trial of INCB54828 in bladder cancer |
No record found31 Dec 2016 |
| Incyteannounced 9 Aug 2016 |
Report initial data from the proof-of-concept trial of INCB39110 in GVHD |
No record found31 Dec 2016 |
| Incyteannounced 9 May 2016 |
Initiate the Phase 1/2 trial of INCAGN1876 (GITR) in solid tumors |
Met30 Jun 2016 |
| Incyteannounced 9 May 2016 |
Initiate the Phase 1/2 trial of INCAGN1949 (OX40) in solid tumors |
Met31 Dec 2016 |
| Incyteannounced 9 May 2016 |
Begin the U.S. pivotal trial of ruxolitinib for graft versus host disease |
No record found31 Dec 2016 |
| Incyteannounced 11 Feb 2016 |
Initiate the Phase 1/2 study of INCB59872 (LSD1) in advanced malignancies |
No record found30 Jun 2016 |
| Incyteannounced 11 Feb 2016 |
Begin the Phase 3 ECHO-301 study of epacadostat with pembrolizumab in first-line melanoma |
No record found30 Jun 2016 |
| Incyteannounced 11 Feb 2016 |
Recruit over 600 patients into Phase 2 epacadostat expansion cohorts |
No record found31 Dec 2016 |
| Incyteannounced 11 Feb 2016 |
Expect expansion cohorts of INCB54828 (FGFR) in genetically-defined tumor types |
No record found31 Dec 2016 |